si-RNA-mediated gene silencing technology to inhibit tyrosinase and reduce pigmentation
View Patent ↗The present invention describes compositions and methods for treating, preventing and improving hyperpigmentation, or other unwanted pigmentation of the skin, or other unwanted skin condition, such as age spots, aged skin, skin discoloration, etc., wherein the compositions include siRNA-gene silencing oligomers specific for tyrosinase. The compositions are used to treat a broad variety of pigmentation conditions, and are preferably applied to the skin, or are delivered by directed means to a site in need thereof.
1. A cosmetic composition comprising:
one or more siRNA oligomers in an amount effective to ameliorate, reduce, and/or eliminate skin hyperpigmentation or other unwanted skin pigmentation; and a topical cosmetically acceptable vehicle, wherein the siRNA oligomer consists of:
5′-UAGGACCUGCCAGUGCUCUtt-3′ (SEQ ID NO: 1) and
3′-ttAUCCUGGACGGUCACGAGA-5′ (SEQ ID NO: 2).
2. The composition according to claim 1 , wherein the composition is a topical composition.
3. The composition according to claim 2 , wherein the composition is an at least once daily applied composition.
4. The composition according to claim 1 , wherein the one or more siRNA oligomer is present in an amount from about 0.0001 wt % to about 10 wt % of the total weight of the composition.
5. The composition according to claim 1 , wherein the one or more siRNA oligomer is present in an amount from about 0.0005 wt % to about 5 wt % of the total weight of the composition.
6. The composition according to claim 1 , wherein the one or more siRNA oligomer is present in an amount from about 0.001 wt % to about 1 wt % of the total weight of the composition.
7. The composition according to claim 1 , wherein the vehicle is a cosmetically or dermatologically acceptable vehicle.
8. The composition according to claim 1 , wherein the composition further comprises a sunscreen.
9. The composition according to claim 8 , wherein the sunscreen is selected from the group consisting of avobenzone, cinnamic acid derivatives, octyl salicylate, oxybenzone, titanium oxide, zinc oxide and combinations thereof.
10. The composition according to claim 1 , wherein the composition further includes an ingredient selected from the group consisting of an alpha hydroxy acid, a beta hydroxy acid, a keto acid, an oxa acid and an oxa diacid.
11. The composition according to claim 1 , wherein the composition is administered via a transdermal patch.